Why is the concept of spondyloarthropathies important?

Best Practice and Research: Clinical Rheumatology

Volumn 16, Issue 4, 2002, Pages 495-505

  Dougados, Maxime ^a   Hochberg, Marc C ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Classification criteria; Diagnostic criteria; Spondyloarthropathy

Indexed keywords

HLA B27 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTHRALGIA; ARTHRITIS; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; CONCEPT FORMATION; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; EARLY DIAGNOSIS; ENTERITIS; EPIDEMIOLOGICAL DATA; EUROPE; FAMILIAL DISEASE; HEALTH CARE COST; HEALTH ECONOMICS; HEEL PAIN; HUMAN; IRIDOCYCLITIS; NONHUMAN; PATIENT CODING; PATIENT EDUCATION; PATIENT MONITORING; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; UNITED STATES; UVEITIS; ARTHROPATHY; SPINE DISEASE; ERYTHROCYTE SEDIMENTATION RATE; SYMPTOM;

HUMANS; JOINT DISEASES; SPINAL DISEASES;

EID: 0036727905     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6942(02)90253-6     Document Type: Review

References (38)

1. Arnett FC. Seronegative spondylarthropathies. Bulletin of the Rheumatic Diseases 1987; 37: 1-12.
2. Moll JMH, Haslock I, MacRae IF & Wright V. Associations between ankylosing spondylitis, psoriatic arthritis. Reiter's Disease, the intestinal arthropathies, and Behcet's syndrome. Medicine (Baltimore) 1974; 53: 343-364.
3. Schumacher HR & Bardin T. The spondylarthropathies: Classification and diagnosis: Do we need new terminologies. Baillière's Clinical Rheumatology 1998 12: 551-565.
4. Al Khonizy W & Reveille JD. The immunogenetics of the seronegative spondylarthropathies. Baillière's Clinical Rheumatology 1998; 12: 567-587.
5. Breban M. Animal models and in vitro models for the study of aetiopathogenesis of spondyloarthropathies. Baillière's Clinical Rheumatology 1998; 12: 611-626.
6. Dougados M, Van Der Linden S, Juhlin R et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis & Rheumatism 1991; 34: 1218-1227.
7. Silman AJ. Ankylosing spondylitis and spondyloarthropathies. In Silman AJ & Hochberg MC (eds) Epidemiology of the Rheumatic Disease, 2nd edn, pp 100-111. Oxford: Oxford University Press, 2001.
8. Carter ET, McKenna CH, Brian DD & Kurland LT. Epidemiology of ankylosing spondylitis in Rochester, Minnesota, 1935-73. Arthritis & Rheumatism 1979; 22: 365-370.
9. Silman AJ. Psoriatic arthropathy. In Silman AJ & Hochberg MC (eds) Epidemiology of the Rheumatic Diseases, 2nd edn, pp 85-89. Oxford: Oxford University Press, 2001.
10. Uramoto K, Shbeeb M, Sunku J et al. The epidemiology of psoriatic arthritis in Olmsted County, 1980-91. Arthritis & Rheumatism 1997; 40: 1100.
11. Silman AJ. Reactive arthritis and Reiter's syndrome. In Silman AJ & Hochberg MC (eds) Epidemiology of the Rheumatic Diseases, 2nd edn, pp 112-120. Oxford: Oxford University Press, 2001.
12. Saraux A, Guedes C, Allain J et al. Prevalence of rheumatoid arthritis and spondylarthropathy in Britany, France. Journal of Rheumatology 1999; 26: 2622-2627.
13. Braun J, Bollow M, Remlinger G et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis & Rheumatism 1998; 41: 58-67.
14. Van Der Linden S, Valkenburg HA & Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modifications of the New York criteria. Arthritis & Rheumatism 1984; 27: 361-368.
15. Willkens RF, Arnett FC, Bitter T et al. Reiter's syndrome. Evaluation of preliminary criteria for definite disease. Arthritis & Rheumatism 1981; 24: 844-849.
16. Vasey F & Espinoza LR. In Calin A (ed.) Psoriatic Arthropathy, Spondylarthropathies. Orlando: Grune & Stratton, 1984.
17. Amor B, Dougados M & Mijiyawa M. Critères de classification des spondylarthropathies. Revue du Rhumatis et des Maladies Osteoarticulaire 1990; 57: 85-89.
18. Amor B, Dougados M, Listrat V et al. Les critères des spondylarthropathies. Critères de classification et/ou d'aide au diagnostic? Revue du Rhumatis et des Maladies Osteoarticulaire (French Edition) 1995; 62: 11-16.
19. Dougados M. Ankylosing spondylitis. Orphanet encyclopedia, November 2001, http://orphanet.infobiogen.fr/data/patho/GB/uk-AS.html.
20. Peppercorn MA. Sulfasalazine: Pharmacology, clinical use, toxicity and related new drug development. Annals of Internal Medicine 1984; 101: 377-386.
21. Mielants R & Veys EM. Inflammation of the ileum in patients with B27 positive reactive arthritis. Lancet 1984; 1: 288.
22. Dougados M, Alemani M, Tulliez M et al. Ileocolonoscopie systématique au cours des spondyloarthropathies séronégatives. Revue du Rhumatis et des Maladies Osteoarticulaire 1987; 54: 279-283.
23. Dougados M, Boumier P & Amor B. Sulphasalazine in ankylosing spondylitis: A double blind controlled study in 60 patients. British Medical Journal 1986; 293: 911-914.
24. Feltelius N & Allgren R. Sulphasalazine in ankylosing spondylitis. Annals of the Rheumatic Diseases 1986; 45: 396-399.
25. Nissila M, Lehtinen K, Leirisalo-Repo M et al. Sulphasalazine in the treatment of ankylosing spondylitis. Arthritis & Rheumatism 1988; 31: 1111-1116.
26. Dougados M, Van Der Linden S, Leirisalo-Repo M et al. Sulfasalazine: A randomized multicentre, double-blind, placebo-controlled study. Arthritis & Rheumatism 1995; 35: 618-627.
27. Dougados M, Berenbaum F, Maetzel A & Amor B. Prevention des épisodes d'uvéite antérieure aiguë des spondylarthropathies par la salazosulfapyridine. Revue du Rhumatis et des Maladies Osteoarticulaire (French Edition) 1993; 60: 81-83.
28. Clegg DO, Reda DJ & Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study. Arthritis & Rheumatism 1999; 42: 2325-2329.
29. Brandt J, Haibel H, Cornely D et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis & Rheumatism 2000; 43: 1346-1352.
30. Braun J & Sieper J. Anti TNF-α: A new dimension in the pharmacotherapy of the spondyloarthropathies? Annals of the Rheumatic Diseases 2000; 59: 404-406.
31. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine 1999; 340: 1398-1405.
32. D'Agostino MA, Breban M, Said-Nahal R & Dougados M. Refractory inflammatory heel pain in spondylarthropathy: A dramatic response to infliximab documented by ultrasound. Arthritis & Rheumatism 2002 (in press).
33. Said-Nahal R, Miceli-Richard C, D'Agostino MA et al. Phenotypic diversity is not determined by independent genetic factors in familial spondylarthropathy. Arthritis & Rheumatism 2001; 45: 478-484.
34. Kidd BL & Cawley MI. Delay in diagnosis of spondylarthritis. British Journal of Rheumatology 1988; 27: 230-232.
35. Calin A. The material history and prognosis of ankylosing spondylitis. Journal of Rheumatology 1985; 15: 1054-1055.
36. Amor B, Silva Santos R, Nahal R et al. Predictive factors of the long term outcome of spondylarthropathies. Journal of Rheumatology 1994; 21: 1883-1887.
37. Claudepierre P, Flipo RM, Sibilia J et al. The patients knowledge about their disease: A French multicentric survey in ankylosing spondylitis (AS). EULAR 2001 abstract. Annals of the Rheumatic Diseases 2001; 6 (supplement I): 5 (OP0057).
38. Toivenen A & Khan MA. Therapeutic dilemmas in ankylosing spondylitis and related spondylarthropathies. Rheumatology Reviews 1994; 3: 21-27.